Source-grounded facts extracted from Alto Neuroscience, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Andrew Miller was appointed as Director at Alto Neuroscience, Inc..
“the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Board’s Nominating and Corporate Governance Committee (the “NCGC”), unanimously appointed Andrew Miller, Ph.D. to serve as a member of the Board.”
Alto Neuroscience, Inc. shareholders approved Amendment and restatement of 2024 Employee Stock Purchase Plan to treat outstanding pre-funded warrants the same as outstanding shares of common stock for purposes of calculating the number of shares to be automatically added to the share reserve thereunder pursuant to the evergreen feature at the 2026-05-12 meeting.
“The votes cast at the Annual Meeting regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 11,946,818 11,097,535 120,240 3,598,216”
Alto Neuroscience, Inc. shareholders rejected Amendment and restatement of 2024 Equity Incentive Plan to treat outstanding pre-funded warrants the same as outstanding shares of common stock for purposes of calculating the number of shares to be automatically added to the share reserve thereunder pursuant to the evergreen feature at the 2026-05-12 meeting.
“The votes cast at the Annual Meeting regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 10,838,509 12,205,864 120,220 3,598,216”
Alto Neuroscience, Inc. shareholders approved Ratification of the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-12 meeting.
“The votes cast at the Annual Meeting regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 26,727,215 23,440 12,154 0”
Alto Neuroscience, Inc. shareholders approved Election of Class II directors at the 2026-05-12 meeting.
“The votes cast at the Annual Meeting regarding this proposal were as follows: Name Votes For Votes Withheld Broker Non-Votes Raymond Sanchez, M.D. 23,133,161 31,432 3,598,216 Gwill York 12,385,501 10,779,092 3,598,216”
Alto Neuroscience, Inc. reported financial results for the quarter ended March 31, 2026.
“On May 13, 2026, Alto Neuroscience, Inc. (the “Company”) reported financial results for the fiscal quarter ended March 31, 2026.”
Alto Neuroscience, Inc. reported financial results for full year ended December 31, 2025.
“On March 16, 2026, Alto Neuroscience, Inc. (the “Company”) reported financial results for the fiscal year ended December 31, 2025.”
Alto Neuroscience, Inc. issued pre-funded warrants to purchase 3,100,000 shares of Common Stock of warrant to institutional investors for purchase price for the Pre-Funded Warrants is the Purchase Price minus $0.0001 per Pre-Funded Warrant.
“to sell and issue to the Purchasers in a private placement transaction (the “ Private Placement ”) (i) 2,900,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 (“ Common Stock ”), and (ii) with respect to certain Purchasers, pre-funded warrants to purchase 3,100,000 shares of Common Stock (the “ Pre-Funded Warrants ”) in lieu of Shares.”
Alto Neuroscience, Inc. issued 2,900,000 shares of common stock to institutional investors for $20.00 per share.
“Purchasers, pre-funded warrants to purchase 3,100,000 shares of Common Stock (the “ Pre-Funded Warrants ”) in lieu of Shares. The purchase price per share of Common Stock is $20.00 per share (the “ Purchase Price ”) and the purchase price for the Pre-Funded Warrants is the Purchase Price minus $0.0001 per Pre-Funded Warrant. The Company anticipates receiving”
Alto Neuroscience, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $120.0 million (effective 2026-03-16).
“On March 16, 2026, Alto Neuroscience, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional investors (the “ Purchasers ”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction (the “ Private Placement ”) (i) 2,900,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 (“ Common Stock ”), and (ii) with respect to certain Purchasers, pre-funded warrants to purchase 3,100,000 shares of Common Stock (the “ Pre-Funded Warrants ”) in lieu of Shares.”
Maha Radhakrishnan departed as Director at Alto Neuroscience, Inc..
“Also on March 17, 2025, Maha Radhakrishnan, M.D. informed the Company's board of directors (the "Board") that she will not stand for re-election as a Class I director at the Company's 2025 Annual Meeting of Stockholders.”
Jeff (Po Yu) Chen departed as Director at Alto Neuroscience, Inc..
“On March 17, 2025, Jeff (Po Yu) Chen, Ph.D. informed the Company's board of directors (the "Board") that he will not stand for re-election as a Class I director at the Company's 2025 Annual Meeting of Stockholders.”
Michael Hanley was appointed as Chief Operating Officer at Alto Neuroscience, Inc..
“On May 21, 2024, Alto Neuroscience, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Michael Hanley as the Chief Operating Officer of the Company, effective as of May 20, 2024”
Alto Neuroscience, Inc. reported financial results for the first quarter ended March 31, 2024.
“Alto Neuroscience, Inc. (the "Company") reported financial results for the fiscal quarter ended March 31, 2024.”
Alto Neuroscience, Inc. reported financial results for full year ended December 31, 2023.
“On March 21, 2024, Alto Neuroscience, Inc. (the "Company") reported financial results for the full year ended December 31, 2023.”
Maha Radhakrishnan was appointed as Director at Alto Neuroscience, Inc..
“On March 8, 2024, the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCGC”), appointed Maha Radhakrishnan, M.D., to serve as a member of the Board and as a member of the NCGC.”
Alto Neuroscience, Inc.: Adopted amended and restated bylaws in connection with the closing of the IPO (effective 2024-02-06).
“Effective as of February 6, 2024, the Company adopted amended and restated bylaws (the “Restated Bylaws”) in connection with the closing of the IPO. The Board and stockholders previously approved the Restated Bylaws to be effective immediately prior to the closing of the IPO.”
Alto Neuroscience, Inc.: Amended and restated certificate of incorporation in connection with the closing of the IPO (effective 2024-02-06).
“the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware. The Company’s board of directors (the “Board”) and stockholders previously approved the Restated Certificate to be effective as of immediately prior to the closing of the IPO.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.